LLY

1,138

-1.01%↓

JNJ

238.3

+0.36%↑

ABBV

225.39

-0.27%↓

UNH

406.62

-1.33%↓

MRK

118.27

-1.34%↓

LLY

1,138

-1.01%↓

JNJ

238.3

+0.36%↑

ABBV

225.39

-0.27%↓

UNH

406.62

-1.33%↓

MRK

118.27

-1.34%↓

LLY

1,138

-1.01%↓

JNJ

238.3

+0.36%↑

ABBV

225.39

-0.27%↓

UNH

406.62

-1.33%↓

MRK

118.27

-1.34%↓

LLY

1,138

-1.01%↓

JNJ

238.3

+0.36%↑

ABBV

225.39

-0.27%↓

UNH

406.62

-1.33%↓

MRK

118.27

-1.34%↓

LLY

1,138

-1.01%↓

JNJ

238.3

+0.36%↑

ABBV

225.39

-0.27%↓

UNH

406.62

-1.33%↓

MRK

118.27

-1.34%↓

Home・Akcijų sąrašas・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Atidarymo kaina

SektoriusSveikatos priežiūra

10.8 4.45

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

10.08

Max

10.85

Pagrindiniai rodikliai
By Trading Economics
Pajamos	227M
Pardavimai	139M
P/E Sektoriaus vid.	4.094 49.888
Pelno marža	163.843
Darbuotojai	1,796
EBITDA	1.3M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+54.84% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	1.9B
Ankstesnė atidarymo kaina	6.35
Ankstesnė uždarymo kaina	10.8

Naujienos nuotaikos

By Acuity

10%

90%

8 / 344 reitingas Healthcare

Hutchison China MediTech Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-09 23:49; UTC

Rinkos pokalbiai

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

2026-06-09 23:45; UTC

Įsigijimai, susijungimai, perėmimai

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

2026-06-09 23:44; UTC

Įsigijimai, susijungimai, perėmimai

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

2026-06-09 23:44; UTC

Įsigijimai, susijungimai, perėmimai

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

2026-06-09 23:43; UTC

Įsigijimai, susijungimai, perėmimai

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

2026-06-09 23:35; UTC

Rinkos pokalbiai

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

2026-06-09 22:06; UTC

Įsigijimai, susijungimai, perėmimai

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

2026-06-09 22:05; UTC

Įsigijimai, susijungimai, perėmimai

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

2026-06-09 22:05; UTC

Įsigijimai, susijungimai, perėmimai

Samsung: Additional Investment Makes It Largest Shareholder in Element

2026-06-09 22:05; UTC

Įsigijimai, susijungimai, perėmimai

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

2026-06-09 20:51; UTC

Uždarbis

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

2026-06-09 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-09 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-06-09 20:09; UTC

Rinkos pokalbiai

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

2026-06-09 19:36; UTC

Rinkos pokalbiai

Cattle Climbs as Crude Oil Falls -- Market Talk

2026-06-09 19:32; UTC

Rinkos pokalbiai

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

2026-06-09 19:25; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

2026-06-09 19:00; UTC

Rinkos pokalbiai

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

2026-06-09 18:52; UTC

Įsigijimai, susijungimai, perėmimai

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

2026-06-09 18:47; UTC

Rinkos pokalbiai

No World Cup Inflation Seen So Far in Mexico -- Market Talk

2026-06-09 18:37; UTC

Rinkos pokalbiai

Canada's Cooling Trade With the U.S. -- Market Talk

2026-06-09 18:27; UTC

Rinkos pokalbiai

Precious Metals Lower as Trump Vows Military Response -- Market Talk

2026-06-09 17:35; UTC

Rinkos pokalbiai

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

2026-06-09 17:30; UTC

Rinkos pokalbiai

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

2026-06-09 16:34; UTC

Rinkos pokalbiai

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

2026-06-09 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-09 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-06-09 16:20; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Health Care Roundup: Market Talk

2026-06-09 15:28; UTC

Rinkos pokalbiai

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

2026-06-09 15:25; UTC

Rinkos pokalbiai

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Akcijų palyginimas

Kainos pokytis

Hutchison China MediTech Ltd ADR Prognozė

Kainos tikslas

By TipRanks

54.84% į viršų

12 mėnesių prognozė

Vidutinis 16.8 USD 54.84%

Aukščiausias 20 USD

Žemiausias 13.6 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Hutchison China MediTech Ltd ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

Pirkti

Laikyti

Parduoti

Remiantis 2 analitikų, pateikusių Hutchison China MediTech Ltd ADR akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

8 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.